Qiagen Consolidates, Invests $10M in Maryland Facilities | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today announced changes to its Maryland operations with the consolidation of three facilities into two and a $10 million investment into the businesses.

As part of the changes, Qiagen will shutter its Gaithersburg manufacturing facility and move it to the company's Germantown site, which will manufacture some of Qiagen's highest volume diagnostics assays, including the digene HC2 HPV Test for cervical cancer prevention.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.